Workflow
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why
Yahoo Finance· 2026-03-01 09:27
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is one of the best cheap biotech stocks to buy now. Guggenheim lifted the price target on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) to $25 from $20 on February 27, maintaining a Buy rating on the shares and telling investors that it updated its model to reflect fiscal Q4 financials, and continues to be “encouraged” by the company’s goal to achieve profitability in early Q3 of 2026. The rating update came after Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) annou ...
Is Halozyme Therapeutics (HALO) a Buy Post Earnings?
Yahoo Finance· 2026-03-01 09:27
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best cheap biotech stocks to buy now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received several bullish rating updates from analysts following its earnings release. Morgan Stanley lifted the price target on the stock to $94 from $78 on February 19, maintaining an Overweight rating on the shares after Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported “strong” Q4 results. It told investors in a research note that it believes 2026 to be “another st ...
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025
Yahoo Finance· 2026-03-01 09:27
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is one of the best cheap biotech stocks to buy now. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and twelve months ended December 31, 2025, on February 26, 2026. It reported that total revenue for the three and twelve months was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million in the prior year periods, respectively. Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks ...
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results
Yahoo Finance· 2026-03-01 09:27
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best cheap biotech stocks to buy now. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported record fiscal Q4 and record full year 2025 financial results on February 25. Total revenues for the full year 2025 came up to $589.0 million, reflecting a 19.8% year-over-year growth and marking another year of record total revenues for the company. Total revenues for fiscal Q4 2025 were $152.6 million, supported by an 18.3% FIRDAPSE® growth and 67.5% growth ...
Wells Fargo Cuts PT on Sarepta Therapeutics (SRPT) to $38 From $45
Yahoo Finance· 2026-03-01 09:27
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the best cheap biotech stocks to buy now. On February 27, Wells Fargo cut the price target on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $38 from $45 while maintaining an Overweight rating on the shares. The firm stated that, given 2026 guidance, it appears that the GTx launch reset post safety events could take longer than it expected, and thus it adjusted its ELEVIDYS numbers, arriving at a new price target. That said, Wells Fargo anticipates the siRNA ...
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31
Yahoo Finance· 2026-03-01 09:27
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best cheap biotech stocks to buy now. On February 25, Deutsche Bank adjusted the price target on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to $30 from $31 and reiterated a Hold rating on the shares, updating its model on the stock post the fiscal Q4 report. Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported strong 2025 financial results on F ...
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why
Insider Monkey· 2026-03-01 09:27
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025
Yahoo Finance· 2026-03-01 09:27
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the best cheap biotech stocks to buy now. TG Therapeutics, Inc. (NASDAQ:TGTX) released financial results for fiscal Q4 and full year 2025 on February 26. It reported fiscal Q4 and full year 2025 total revenue of $192.6 million and $616.3 million, respectively, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively. U.S. net product revenue for BRIUMVI reached $182.7 million for fiscal Q4 2025, reflecting around 20% quarterly growt ...
Wells Fargo Cuts PT on Soleno Therapeutics (SLNO) to $110 From $114 – Here’s Why
Yahoo Finance· 2026-03-01 09:27
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best cheap biotech stocks to buy now. Wells Fargo cut the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $110 from $114 on February 27, reaffirming an Overweight rating on the shares and stating that while some investors’ near-term takeout thesis may be removed by the management’s commentary on building out a pipeline plus LCM for Vykat XR and the CFO’s retirement, shares remain cheap relative to expected FY26 revenue and cash flow, and the ...
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here’s Why
Yahoo Finance· 2026-03-01 09:27
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best cheap biotech stocks to buy now. Canaccord lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $104 from $98 on February 26 and reiterated a Buy rating on the shares. It stated that while the company’s fiscal Q4 2025 earnings showed a slight top-line beat, they were otherwise uneventful, following BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) recent announcement of the acquisition of Amicus and updates at the January investor ...